Neuropathological criteria of anti-IgLON5-related tauopathy
Open Access
- 29 June 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica
- Vol. 132 (4), 531-543
- https://doi.org/10.1007/s00401-016-1591-8
Abstract
We recently reported a novel neurological syndrome characterized by a unique NREM and REM parasomnia with sleep apnea and stridor, accompanied by bulbar dysfunction and specific association with antibodies against the neuronal cell-adhesion protein IgLON5. All patients had the HLA-DRB1*1001 and HLA-DQB1*0501 alleles. Neuropathological findings in two patients revealed a novel tauopathy restricted to neurons and predominantly involving the hypothalamus and tegmentum of the brainstem. The aim of the current study is to describe the neuropathological features of the anti-IgLON5 syndrome and to provide diagnostic levels of certainty based on the presence of associated clinical and immunological data. The brains of six patients were examined and the features required for the neuropathological diagnosis were established by consensus. Additional clinical and immunological criteria were used to define “definite”, “probable” and “possible” diagnostic categories. The brains of all patients showed remarkably similar features consistent with a neurodegenerative disease with neuronal loss and gliosis and absence of inflammatory infiltrates. The most relevant finding was the neuronal accumulation of hyperphosphorylated tau composed of both three-repeat (3R) and four-repeat (4R) tau isoforms, preferentially involving the hypothalamus, and more severely the tegmental nuclei of the brainstem with a cranio-caudal gradient of severity until the upper cervical cord. A “definite” diagnosis of anti-IgLON5-related tauopathy is established when these neuropathological features are present along with the detection of serum or CSF IgLON5 antibodies. When the antibody status is unknown, a “probable” diagnosis requires neuropathological findings along with a compatible clinical history or confirmation of possession of HLA-DRB1*1001 and HLA-DQB1*0501 alleles. A “possible” diagnosis should be considered in cases with compatible neuropathology but without information about a relevant clinical presentation and immunological status. These criteria should help to identify undiagnosed cases among archival tissue, and will assist future clinicopathological studies of this novel disorder.Keywords
Funding Information
- fundacio marato de TV3 (20141610)
- Fondo de Investigaciones Sanitarias, FEDER (15/00377)
- Fondo de Investigaciones Sanitarias (FIS 14/00203)
- CIBERER
- National Institutes of Health (NIH RO1NS077851)
This publication has 17 references indexed in Scilit:
- Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodiesMovement Disorders, 2016
- IgLON5 autoimmunity and abnormal behaviours during sleepThe Lancet, 2015
- Primary age-related tauopathy (PART): a common pathology associated with human agingActa Neuropathologica, 2014
- Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 YearsJournal of Neuropathology and Experimental Neurology, 2011
- Multiple System AtrophyPublished by Wiley ,2011
- Progressive Supranuclear Palsy and Corticobasal DegenerationPublished by Wiley ,2011
- Upper Airway Dysfunction of Tau-P301L Mice Correlates with Tauopathy in Midbrain and Ponto-Medullary Brainstem NucleiJournal of Neuroscience, 2010
- IgLON cell adhesion molecule Kilon is a crucial modulator for synapse number in hippocampal neuronsBrain Research, 2008
- Achalasie de l’œsophage, troubles du sommeil et mouvements choréiques au cours d’une taupathie sans ophtalmoplégie, syndrome parkinsonien ni démence (paralysie supranucléaire progressive ?) : étude clinicopathologiqueRevue Neurologique, 2008
- Selective Neurofibrillary Degeneration of the Hippocampal CA2 Sector Is Associated with Four-Repeat TauopathiesJournal of Neuropathology and Experimental Neurology, 2002